55154-71-7Relevant articles and documents
-
Carroll,Coleman
, p. 318,319 (1975)
-
NOpiates: Novel dual action neuronal nitric oxide synthase inhibitors with μ-opioid agonist activity
Renton, Paul,Green, Brenda,Maddaford, Shawn,Rakhit, Suman,Andrews, John S.
, p. 227 - 231 (2012/05/04)
A novel series of benzimidazole designed multiple ligands (DMLs) with activity at the neuronal nitric oxide synthase (nNOS) enzyme and the μ-opioid receptor was developed. Targeting of the structurally dissimilar heme-containing enzyme and the μ-opioid GPCR was predicated on the modulatory role of nitric oxide on μ-opioid receptor function. Structure-activity relationship studies yielded lead compound 24 with excellent nNOS inhibitory activity (IC50 = 0.44 μM), selectivity over both endothelial nitric oxide synthase (10-fold) and inducible nitric oxide synthase (125-fold), and potent μ-opioid binding affinity, Ki = 5.4 nM. The functional activity as measured in the cyclic adenosine monosphospate secondary messenger assay resulted in full agonist activity (EC50 = 0.34 μM). This work represents a novel approach in the development of new analgesics for the treatment of pain.